VRTX
VRTXXNAS

Vertex Pharmaceuticals Inc

Market cap $130.9B

$508.54

+125.42 (+32.74%)past year

VRTX

$508.54

-1.51% today

Market price$508.54
Shares1
Est. total$508.54

Buy with €1M virtual cash · No real money

Vertex Pharmaceuticals Inc (VRTX) is a publicly traded company listed on the XNAS. As of September 18, 2026, Invest's signal rates VRTX a Buy, with the stock up 31% over the past year. You can practice trading VRTX risk-free with €1,000,000 in virtual cash.

Key stats

As of September 18, 2026

Market Cap

$130.9B

Volume

418K

52-wk High

$560.25

52-wk Low

$374.17

Day High

$518.10

Day Low

$508.23

P/E (TTM)

29.62

Revenue (TTM)

$12.6B

EPS (TTM)

$17.17

Performance

1M

-7.9%

6M

+11.0%

1Y

+31.4%

Invest signal · VRTX

Buy
SellHoldBuy
1-year trend+31%
3-month momentum+13%
Valuation (P/E)29.6
Revenue growth (QoQ)+11.6%
Profitability (EPS)Profitable

Algorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.

VRTX overview

AI overview

Revenue & EPS — last 8 quarters

QoQ rev +11.6%

Revenue

$3B
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Q2 '26

EPS (diluted)

$4.31 per share
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26
Q2 '26

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults.

Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Employees

6,400

www.vrtx.com

30-Day Win Rate · VRTX

54%WIN RATE
Up days

13 days

Down days

11 days

Last 24 sessions

How to practice trading VRTX

  1. 1

    Use the VRTX buy panel above

    Set a quantity and hit Buy at the real market price — right here, nothing to download.

  2. 2

    Trade with €1,000,000 virtual cash

    You get a million in virtual money instantly to invest, risk-free.

  3. 3

    Create a free account to save it

    Sign up in seconds to keep your portfolio and track its performance.

  4. 4

    Track and compete

    Watch your portfolio grow and climb the global leaderboard — or start a private league.

  5. 5

    Prefer mobile? Get the iOS app

    Invest is also free on the App Store, synced with your web account.

Top VRTX traders on Invest

Full leaderboard
🥇Nora K.+95.0%
🥈james_doyle+86.0%
🥉Julia M.+83.0%
#4noah_b+74.0%
#5Priya S.+65.0%

Frequently asked questions

Is VRTX a good stock to buy right now?

As of September 18, 2026, Invest's signal rates VRTX a Buy, based on its price trend, valuation, and fundamentals (P/E around 29.6), with the stock up 31% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading VRTX risk-free first.

What is Vertex Pharmaceuticals Inc's (VRTX) market cap?

Vertex Pharmaceuticals Inc has a market capitalization of approximately $130.9B, on trailing-twelve-month revenue of about $12.6B.

How has VRTX stock performed?

VRTX is up 31% over the past year and up 11% over six months. Its 52-week range runs roughly from $374.17 to $560.25. Past performance doesn't predict future results.

How can I practice trading VRTX for free?

On Invest you get €1,000,000 in virtual cash and can buy VRTX at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.

More stocks to practice

Compare VRTX with peers

Invest — Stock Market SimulatorNot financial advice.